MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom.
Vaccine. 2010 Oct 21;28(45):7306-12. doi: 10.1016/j.vaccine.2010.08.077. Epub 2010 Sep 16.
We investigated whether vaccination of healthy HIV-seronegative and HIV-1-seropositive antiretroviral therapy-treated subjects with recombinant modified vaccinia virus Ankara expressing an HIV-1 immunogen (MVA.HIVA) induced MVA-specific T cell responses. Using IFN-γ Elispot assays, we observed new or increased responses to MVA virus in 52% of HIV-seronegative subjects and 93% HIV-1 seropositive subjects; MVA-specific T cell frequencies were generally low and correlated poorly with T cell responses to the HIV-1 immunogen. In two vaccinees, responses were mapped to CD8+ T cell epitopes present in replication-competent vaccinia virus. These data support further evaluation of MVA as a viral vector for HIV-1 immunogens.
我们研究了表达 HIV-1 免疫原的重组改良安卡拉牛痘病毒（MVA.HIVA）对健康 HIV 血清阴性和接受抗逆转录病毒治疗的 HIV-1 血清阳性个体进行接种，是否能诱导 MVA 特异性 T 细胞应答。使用 IFN-γ Elispot 检测法，我们发现 52%的 HIV 血清阴性个体和 93%的 HIV-1 血清阳性个体对 MVA 病毒出现新的或增强的应答；MVA 特异性 T 细胞频率通常较低，与对 HIV-1 免疫原的 T 细胞应答相关性差。在两名疫苗接种者中，应答可被定位至存在于有复制能力的牛痘病毒中的 CD8+ T 细胞表位。这些数据支持进一步评估 MVA 作为 HIV-1 免疫原的病毒载体。
